-
1
-
-
0025268321
-
Rational design of peptide-based HIV proteinase inhibitors
-
Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248, 358-361.
-
(1990)
Science
, vol.248
, pp. 358-361
-
-
Roberts, N.A.1
Martin, J.A.2
Kinchington, D.3
Broadhurst, A.V.4
Craig, J.C.5
Duncan, I.B.6
Galpin, S.A.7
Handa, B.K.8
Kay, J.9
Krohn, A.10
Lambert, R.W.11
Merrett, J.H.12
Mills, J.S.13
Parkes, K.E.B.14
Redshaw, S.15
Ritchie, A.J.16
Taylor, D.L.17
Thomas, G.J.18
Machin, P.J.19
-
2
-
-
0027969994
-
L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor
-
Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
-
(1994)
J. Med. Chem
, vol.37
, pp. 3443-3451
-
-
Dorsey, B.D.1
Levin, R.B.2
McDaniel, S.L.3
Vacca, J.P.4
Guare, J.P.5
Darke, P.L.6
Zugay, J.A.7
Emini, E.A.8
Schleif, W.A.9
Quintero, J.C.10
Lin, J.H.11
Chen, I.-W.12
Holloway, M.K.13
Fitzgerald, P.M.D.14
Axel, M.G.15
Ostovic, D.16
Anderson, P.S.17
Huff, J.R.18
-
3
-
-
0028968902
-
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
-
Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X. P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
-
(1995)
Proc. Natl. Acad. Sci. U.S.A
, vol.92
, pp. 2484-2488
-
-
Kempf, D.J.1
Marsh, K.C.2
Denissen, J.F.3
McDonald, E.4
Vasavanonda, S.5
Flentge, C.A.6
Green, B.E.7
Fino, L.8
Park, C.H.9
Kong, X.P.10
Wideburg, N.E.11
Saldivar, A.12
Ruiz, L.13
Kati, W.M.14
Sham, H.L.15
Robins, T.16
Stewart, K.D.17
Hsu, A.18
Plattner, J.J.19
Leonard, J.M.20
Norbeck, D.W.21
more..
-
4
-
-
14444281534
-
Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease
-
Kaldor, S. W.; Kalish, V. J.; Davies, J. F., II; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
-
(1997)
J. Med. Chem
, vol.40
, pp. 3979-3985
-
-
Kaldor, S.W.1
Kalish, V.J.2
Davies II, J.F.3
Shetty, B.V.4
Fritz, J.E.5
Appelt, K.6
Burgess, J.A.7
Campanale, K.M.8
Chirgadze, N.Y.9
Clawson, D.K.10
Dressman, B.A.11
Hatch, S.D.12
Khalil, D.A.13
Kosa, M.B.14
Lubbehusen, P.P.15
Muesing, M.A.16
Patick, A.K.17
Reich, S.H.18
Su, K.S.19
Tatlock, J.H.20
more..
-
5
-
-
0028846226
-
Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
-
Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
-
(1995)
J. Am. Chem. Soc
, vol.117
, pp. 1181-1182
-
-
Kim, E.E.1
Baker, C.T.2
Dwyer, M.D.3
Murcko, M.A.4
Rao, B.G.5
Tung, R.D.6
Navia, M.A.7
-
6
-
-
0031788930
-
-
Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C. M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
-
Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C. M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
-
-
-
-
7
-
-
0033931167
-
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents
-
Robinson, B. S.; Riccardi, K. A.; Gong, Y. F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P. F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 2000, 44, 2093-2099.
-
(2000)
Antimicrob. Agents Chemother
, vol.44
, pp. 2093-2099
-
-
Robinson, B.S.1
Riccardi, K.A.2
Gong, Y.F.3
Guo, Q.4
Stock, D.A.5
Blair, W.S.6
Terry, B.J.7
Deminie, C.A.8
Djang, F.9
Colonno, R.J.10
Lin, P.F.11
-
8
-
-
12944322516
-
-
Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M. M.; Lynn, J. C.; Chong, K. T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 1998, 41, 3467-3476.
-
Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M. M.; Lynn, J. C.; Chong, K. T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 1998, 41, 3467-3476.
-
-
-
-
9
-
-
10744226241
-
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro
-
Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 2003, 47, 3123-3129.
-
(2003)
Antimicrob. Agents Chemother
, vol.47
, pp. 3123-3129
-
-
Koh, Y.1
Nakata, H.2
Maeda, K.3
Ogata, H.4
Bilcer, G.5
Devasamudram, T.6
Kincaid, J.F.7
Boross, P.8
Wang, Y.F.9
Tie, Y.10
Volarath, P.11
Gaddis, L.12
Harrison, R.W.13
Weber, I.T.14
Ghosh, A.K.15
Mitsuya, H.16
-
10
-
-
6344231715
-
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor
-
King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Wigerinck, P.; de Bethune, M. P.; Schiffer, C. A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 2004, 78, 12012-12021.
-
(2004)
J. Virol
, vol.78
, pp. 12012-12021
-
-
King, N.M.1
Prabu-Jeyabalan, M.2
Nalivaika, E.A.3
Wigerinck, P.4
de Bethune, M.P.5
Schiffer, C.A.6
-
11
-
-
20144382495
-
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor
-
Surleraux, D. L.; Tahri, A.; Verschueren, W. G.; Pille, G. M.; de Kock, H. A.; Jonckers, T. H.; Peeters, A.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M. P.; King, N. M.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 2005, 48, 1813-1822.
-
(2005)
J. Med. Chem
, vol.48
, pp. 1813-1822
-
-
Surleraux, D.L.1
Tahri, A.2
Verschueren, W.G.3
Pille, G.M.4
de Kock, H.A.5
Jonckers, T.H.6
Peeters, A.7
De Meyer, S.8
Azijn, H.9
Pauwels, R.10
de Bethune, M.P.11
King, N.M.12
Prabu-Jeyabalan, M.13
Schiffer, C.A.14
Wigerinck, P.B.15
-
12
-
-
19544386471
-
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
-
De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M. P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 2005, 49, 2314-2321.
-
(2005)
Antimicrob. Agents Chemother
, vol.49
, pp. 2314-2321
-
-
De Meyer, S.1
Azijn, H.2
Surleraux, D.3
Jochmans, D.4
Tahri, A.5
Pauwels, R.6
Wigerinck, P.7
de Bethune, M.P.8
-
13
-
-
0031804609
-
Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
-
Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
-
(1998)
Annu. Rev. Biophys. Biomol. Struct
, vol.27
, pp. 249-284
-
-
Wlodawer, A.1
Vondrasek, J.2
-
14
-
-
0035958773
-
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
-
Bartlett, J. A.; DeMasi, R.; Quinn, J.; Moxham, C.; Rousseau, F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001, 15, 1369-1377.
-
(2001)
AIDS
, vol.15
, pp. 1369-1377
-
-
Bartlett, J.A.1
DeMasi, R.2
Quinn, J.3
Moxham, C.4
Rousseau, F.5
-
15
-
-
0034604265
-
3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
-
Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Meibohm, A.; Condra, J. H.; Valentine, F. T.; McMahon, D.; Gonzalez, C.; Jonas, L.; Emini, E. A.; Chodakewitz, J. A.; Isaacs, R.; Richman, D. D. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 2000, 133, 35-39.
-
(2000)
Ann. Intern. Med
, vol.133
, pp. 35-39
-
-
Gulick, R.M.1
Mellors, J.W.2
Havlir, D.3
Eron, J.J.4
Meibohm, A.5
Condra, J.H.6
Valentine, F.T.7
McMahon, D.8
Gonzalez, C.9
Jonas, L.10
Emini, E.A.11
Chodakewitz, J.A.12
Isaacs, R.13
Richman, D.D.14
-
16
-
-
0028943992
-
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
-
Condra, J. H.; Schleif, W. A.; Blahy, O. M.; Gabryelski, L. J.; Graham, D. J.; Quintero, J. C.; Rhodes, A.; Robbins, H. L.; Roth, E.; Shivaprakash, M.; Titus, D.; Yang, T.; Tepplert, H.; Squires, K. E.; Deutsch, P. J.; Emini, E. A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374, 569-571.
-
(1995)
Nature
, vol.374
, pp. 569-571
-
-
Condra, J.H.1
Schleif, W.A.2
Blahy, O.M.3
Gabryelski, L.J.4
Graham, D.J.5
Quintero, J.C.6
Rhodes, A.7
Robbins, H.L.8
Roth, E.9
Shivaprakash, M.10
Titus, D.11
Yang, T.12
Tepplert, H.13
Squires, K.E.14
Deutsch, P.J.15
Emini, E.A.16
-
17
-
-
1442355578
-
HIV drug resistance. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: Implications for inhibitor design
-
Clavel, F.; Hance, A. J. HIV drug resistance. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: Implications for inhibitor design. N. Engl. J. Med. 2004, 350, 1023-1035.
-
(2004)
N. Engl. J. Med
, vol.350
, pp. 1023-1035
-
-
Clavel, F.1
Hance, A.J.2
-
18
-
-
33144463756
-
Ultra-potent Pl modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
-
Miller, J. F.; Andrews, C. W.; Brieger, M.; Furfine, E. S.; Hale, M. R.; Hanlon, M. H.; Hazen, R. J.; Kaldor, I.; McLean, E. W.; Reynolds, D. Ultra-potent Pl modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385. Bioorg. Med. Chem. Lett. 2006, 16, 1788-1794.
-
(2006)
Bioorg. Med. Chem. Lett
, vol.16
, pp. 1788-1794
-
-
Miller, J.F.1
Andrews, C.W.2
Brieger, M.3
Furfine, E.S.4
Hale, M.R.5
Hanlon, M.H.6
Hazen, R.J.7
Kaldor, I.8
McLean, E.W.9
Reynolds, D.10
-
19
-
-
20144385196
-
Design of HIV-1 protease inhibitors active on multidrug-resistant virus
-
Surleraux, D. L.; de Kock, H. A.; Verschueren, W. G.; Pille, G. M.; Maes, L. J.; Peeters, A.; Vendeville, S.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M. P.; King, N. M.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J. Med. Chem. 2005, 48, 1965-1973.
-
(2005)
J. Med. Chem
, vol.48
, pp. 1965-1973
-
-
Surleraux, D.L.1
de Kock, H.A.2
Verschueren, W.G.3
Pille, G.M.4
Maes, L.J.5
Peeters, A.6
Vendeville, S.7
De Meyer, S.8
Azijn, H.9
Pauwels, R.10
de Bethune, M.P.11
King, N.M.12
Prabu-Jeyabalan, M.13
Schiffer, C.A.14
Wigerinck, P.B.15
-
20
-
-
33646172086
-
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
-
Randolph, J. T.; Huang, P. P.; Flosi, W. J.; DeGoey, D.; Klein, L. L.; Yeung, C. M.; Flentge, C.; Sun, M.; Zhao, C.; Dekhtyar, T. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors. Bioorg. Med. Chem. 2006, 14, 4035-4046.
-
(2006)
Bioorg. Med. Chem
, vol.14
, pp. 4035-4046
-
-
Randolph, J.T.1
Huang, P.P.2
Flosi, W.J.3
DeGoey, D.4
Klein, L.L.5
Yeung, C.M.6
Flentge, C.7
Sun, M.8
Zhao, C.9
Dekhtyar, T.10
-
21
-
-
33747479539
-
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
-
Ghosh, A. K.; Sridhar, P. R.; Leshchenko, S.; Hussain, A. K.; Li, J.; Kovalevsky, A. Y.; Walters, D. E.; Wedekind, J. E.; Grum-Tokars, V.; Das, D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I. T.; Mitsuya, H. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem. 2006, 49, 5252-5261.
-
(2006)
J. Med. Chem
, vol.49
, pp. 5252-5261
-
-
Ghosh, A.K.1
Sridhar, P.R.2
Leshchenko, S.3
Hussain, A.K.4
Li, J.5
Kovalevsky, A.Y.6
Walters, D.E.7
Wedekind, J.E.8
Grum-Tokars, V.9
Das, D.10
Koh, Y.11
Maeda, K.12
Gatanaga, H.13
Weber, I.T.14
Mitsuya, H.15
-
22
-
-
5444247213
-
Combating susceptibility to drug resistance: Lessons from HIV-1 protease
-
King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Schiffer, C. A. Combating susceptibility to drug resistance: Lessons from HIV-1 protease. Chem. Biol. 2004, 11, 1333-1338.
-
(2004)
Chem. Biol
, vol.11
, pp. 1333-1338
-
-
King, N.M.1
Prabu-Jeyabalan, M.2
Nalivaika, E.A.3
Schiffer, C.A.4
-
23
-
-
33845492104
-
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands
-
Ali, A.; Reddy, G. S. K. K.; Cao, H.; Anjum, S. G.; Nalam, M. N. L.; Schiffer, C. A.; Rana, T. M. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. J. Med. Chem. 2006, 49, 7342-7356.
-
(2006)
J. Med. Chem
, vol.49
, pp. 7342-7356
-
-
Ali, A.1
Reddy, G.S.K.K.2
Cao, H.3
Anjum, S.G.4
Nalam, M.N.L.5
Schiffer, C.A.6
Rana, T.M.7
-
24
-
-
4344665128
-
Reduction of an enaminone: Synthesis of the diamino alcohol core of ritonavir
-
Haight, A. R.; Stuk, T. L.; Allen, M. S.; Bhagavatula, L.; Fitzgerald, M.; Hannick, S. M.; Kerdesky, F. A. J.; Menzia, J. A.; Parekh, S. I.; Robbins, T. A.; Scarpetti, D.; Tien, J. H. J. Reduction of an enaminone: Synthesis of the diamino alcohol core of ritonavir. Org. Process Res. Dev. 1999, 3, 94-100.
-
(1999)
Org. Process Res. Dev
, vol.3
, pp. 94-100
-
-
Haight, A.R.1
Stuk, T.L.2
Allen, M.S.3
Bhagavatula, L.4
Fitzgerald, M.5
Hannick, S.M.6
Kerdesky, F.A.J.7
Menzia, J.A.8
Parekh, S.I.9
Robbins, T.A.10
Scarpetti, D.11
Tien, J.H.J.12
-
25
-
-
0034374764
-
-
Stoner, E. J.; Cooper, A. J.; Dickman, D. A.; Kolaczkowski, L.; Lallaman, J. E.; Liu, J. H.; Oliver-Shaffer, P. A.; Patel, K. M.; Paterson, J. B.; Plata, D. J.; Riley, D. A.; Sham, H. L.; Stengel, P. J.; Tien, J. H. J. Synthesis of HIV Protease Inhibitor ABT-378 (Lopinavir). Org. Process Res. Dev. 2000, 4, 264-269.
-
Stoner, E. J.; Cooper, A. J.; Dickman, D. A.; Kolaczkowski, L.; Lallaman, J. E.; Liu, J. H.; Oliver-Shaffer, P. A.; Patel, K. M.; Paterson, J. B.; Plata, D. J.; Riley, D. A.; Sham, H. L.; Stengel, P. J.; Tien, J. H. J. Synthesis of HIV Protease Inhibitor ABT-378 (Lopinavir). Org. Process Res. Dev. 2000, 4, 264-269.
-
-
-
-
26
-
-
15144353143
-
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: Candidates for clinical development
-
Bold, G.; Fässler, A.; Capraro, H. G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rosel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hurlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: Candidates for clinical development. J. Med. Chem. 1998, 41, 3387-3401.
-
(1998)
J. Med. Chem
, vol.41
, pp. 3387-3401
-
-
Bold, G.1
Fässler, A.2
Capraro, H.G.3
Cozens, R.4
Klimkait, T.5
Lazdins, J.6
Mestan, J.7
Poncioni, B.8
Rosel, J.9
Stover, D.10
Tintelnot-Blomley, M.11
Acemoglu, F.12
Beck, W.13
Boss, E.14
Eschbach, M.15
Hurlimann, T.16
Masso, E.17
Roussel, S.18
Ucci-Stoll, K.19
Wyss, D.20
Lang, M.21
more..
-
27
-
-
0001271559
-
Carbodiimide-mediated amide formation in a two-phase system. A high-yield and low-racemization procedure for peptide synthesis
-
Ho, G.-J.; Emerson, K. M.; Mathre, D. J.; Shuman, R. F.; Grabowski, E. J. J. Carbodiimide-mediated amide formation in a two-phase system. A high-yield and low-racemization procedure for peptide synthesis. J. Org. Chem. 1995, 60, 3569-3570.
-
(1995)
J. Org. Chem
, vol.60
, pp. 3569-3570
-
-
Ho, G.-J.1
Emerson, K.M.2
Mathre, D.J.3
Shuman, R.F.4
Grabowski, E.J.J.5
-
28
-
-
0029746483
-
Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability
-
Fässler, A.; Bold, G.; Capraro, H. G.; Cozens, R.; Mestan, J.; Poncioni, B.; Rosel, J.; Tintelnot-Blomley, M.; Lang, M. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J. Med. Chem. 1996, 39, 3203-3216.
-
(1996)
J. Med. Chem
, vol.39
, pp. 3203-3216
-
-
Fässler, A.1
Bold, G.2
Capraro, H.G.3
Cozens, R.4
Mestan, J.5
Poncioni, B.6
Rosel, J.7
Tintelnot-Blomley, M.8
Lang, M.9
-
29
-
-
0036308128
-
Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632
-
Xu, Z.; Singh, J.; Schwinden, M. D.; Zheng, B.; Kissick, T. P.; Patel, B.; Humora, M. J.; Quiroz, F.; Dong, L.; Hsieh, D. M.; Heikes, J. E.; Pudipeddi, M.; Lindrud, M. D.; Srivastava, S. K.; Kronenthal, D. R.; Mueller, R. H. Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632. Org. Process Res. Dev. 2002, 6, 323-328.
-
(2002)
Org. Process Res. Dev
, vol.6
, pp. 323-328
-
-
Xu, Z.1
Singh, J.2
Schwinden, M.D.3
Zheng, B.4
Kissick, T.P.5
Patel, B.6
Humora, M.J.7
Quiroz, F.8
Dong, L.9
Hsieh, D.M.10
Heikes, J.E.11
Pudipeddi, M.12
Lindrud, M.D.13
Srivastava, S.K.14
Kronenthal, D.R.15
Mueller, R.H.16
-
30
-
-
12444327171
-
Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands
-
Chen, X.; Kempf, D. J.; Li, L.; Sham, H. L.; Vasavanonda, S.; Wideburg, N. E.; Saldivar, A.; Marsh, K. C.; McDonald, E.; Norbeck, D. W. Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands. Bioorg. Med. Chem. Lett. 2003, 13, 3657-3660.
-
(2003)
Bioorg. Med. Chem. Lett
, vol.13
, pp. 3657-3660
-
-
Chen, X.1
Kempf, D.J.2
Li, L.3
Sham, H.L.4
Vasavanonda, S.5
Wideburg, N.E.6
Saldivar, A.7
Marsh, K.C.8
McDonald, E.9
Norbeck, D.W.10
-
31
-
-
20244387096
-
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments
-
Wu, T. D.; Schiffer, C. A.; Gonzales, M. J.; Taylor, J.; Kantor, R.; Chou, S.; Israelski, D.; Zolopa, A.-R.; Fessel, W. J.; Shafer, R. W. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 2003, 77, 4836-4847.
-
(2003)
J. Virol
, vol.77
, pp. 4836-4847
-
-
Wu, T.D.1
Schiffer, C.A.2
Gonzales, M.J.3
Taylor, J.4
Kantor, R.5
Chou, S.6
Israelski, D.7
Zolopa, A.-R.8
Fessel, W.J.9
Shafer, R.W.10
-
32
-
-
0036280264
-
X-ray crystallographic structure of ABT-378 (Lopinavir) bound to HIV-1 protease
-
Stoll, V.; Qin, W.; Stewart, K. D.; Jakob, C.; Park, C.; Walter, K.; Simmer, R. L.; Helfrich, R.; Bussiere, D.; Kao, J.; Kempf, D.; Sham, H. L.; Norbeck, D. W. X-ray crystallographic structure of ABT-378 (Lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 2002, 10, 2803-2806.
-
(2002)
Bioorg. Med. Chem
, vol.10
, pp. 2803-2806
-
-
Stoll, V.1
Qin, W.2
Stewart, K.D.3
Jakob, C.4
Park, C.5
Walter, K.6
Simmer, R.L.7
Helfrich, R.8
Bussiere, D.9
Kao, J.10
Kempf, D.11
Sham, H.L.12
Norbeck, D.W.13
-
33
-
-
0036147616
-
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease
-
King, N. M.; Melnick, L.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Yang, S. S.; Gao, Y.; Nie, X.; Zepp, C.; Heefner, D. L.; Schiffer, C. A. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 2002, 11, 418-429.
-
(2002)
Protein Sci
, vol.11
, pp. 418-429
-
-
King, N.M.1
Melnick, L.2
Prabu-Jeyabalan, M.3
Nalivaika, E.A.4
Yang, S.S.5
Gao, Y.6
Nie, X.7
Zepp, C.8
Heefner, D.L.9
Schiffer, C.A.10
-
34
-
-
0025099455
-
Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer
-
Matayoshi, E. D.; Wang, G. T.; Krafft, G. A.; Erickson, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 1990, 247, 954-958.
-
(1990)
Science
, vol.247
, pp. 954-958
-
-
Matayoshi, E.D.1
Wang, G.T.2
Krafft, G.A.3
Erickson, J.4
-
35
-
-
0018787723
-
Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors
-
Greco, W. R.; Hakala, M. T. Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. J. Biol. Chem. 1979, 254, 12104-12109.
-
(1979)
J. Biol. Chem
, vol.254
, pp. 12104-12109
-
-
Greco, W.R.1
Hakala, M.T.2
-
36
-
-
0023687234
-
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
-
Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
-
(1988)
J. Virol. Methods
, vol.20
, pp. 309-321
-
-
Pauwels, R.1
Balzarini, J.2
Baba, M.3
Snoeck, R.4
Schols, D.5
Herdewijn, P.6
Desmyter, J.7
De Clercq, E.8
Pauwels, R.9
Balzarini, J.10
Baba, M.11
Snoeck, R.12
Schols, D.13
Herdewijn, P.14
Desmyter, J.15
De Clercq, E.16
-
37
-
-
0037223718
-
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: Structural insights for better antiviral therapy
-
Prabu-Jeyabalan, M.; Nalivaika, E. A.; King, N. M.; Schiffer, C. A. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: Structural insights for better antiviral therapy. J. Virol. 2003, 77, 1306-1315.
-
(2003)
J. Virol
, vol.77
, pp. 1306-1315
-
-
Prabu-Jeyabalan, M.1
Nalivaika, E.A.2
King, N.M.3
Schiffer, C.A.4
-
38
-
-
0005839617
-
-
Purdue University: West Lafayette, Indiana
-
Minor, W. XdisplayF, Purdue University: West Lafayette, Indiana, 1993.
-
(1993)
XdisplayF
-
-
Minor, W.1
-
39
-
-
0031059866
-
Processing of X-ray diffraction data collected in oscillation mode
-
Academic Press: New York
-
Otwinowski, Z.; Minor, W.; Charles W. Carter, Jr. Processing of X-ray diffraction data collected in oscillation mode. In Methods Enzymol.; Academic Press: New York, 1997; Vol. 276, pp 307-326.
-
(1997)
Methods Enzymol
, vol.276
, pp. 307-326
-
-
Otwinowski, Z.1
Minor, W.2
Charles, W.3
Carter, J.4
-
40
-
-
0028103275
-
Number 4. The CCP4suite: Programs for protein crystallography
-
Collaborative Computational Project
-
Collaborative Computational Project, Number 4. The CCP4suite: Programs for protein crystallography. Acta Crystallogr. 1994, D50, 760-763.
-
(1994)
Acta Crystallogr
, vol.D50
, pp. 760-763
-
-
-
41
-
-
84920325457
-
An automated package for molecular replacement
-
Navaza, J. AMoRe: An automated package for molecular replacement. Acta Crystallogr. 1994, A50, 157-163.
-
(1994)
Acta Crystallogr
, vol.A50
, pp. 157-163
-
-
Navaza, J.A.1
-
42
-
-
0034283345
-
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease
-
Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C. A. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 2000, 301, 1207-1220.
-
(2000)
J. Mol. Biol
, vol.301
, pp. 1207-1220
-
-
Prabu-Jeyabalan, M.1
Nalivaika, E.2
Schiffer, C.A.3
-
43
-
-
0036077402
-
ARP/wARP's model-building algorithms. I. The main chain
-
Morris, R. J.; Perrakis, A.; Lamzin, V. S. ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr. 2002, D58, 968-975.
-
(2002)
Acta Crystallogr
, vol.D58
, pp. 968-975
-
-
Morris, R.J.1
Perrakis, A.2
Lamzin, V.S.3
-
45
-
-
13244281317
-
Model-building tools for molecular graphics
-
Emsley, P.; Cowtan, K. Coot; Model-building tools for molecular graphics. Acta Crystallogr. 2004, D60, 2126-2132.
-
(2004)
Acta Crystallogr
, vol.D60
, pp. 2126-2132
-
-
Emsley, P.1
Cowtan2
Coot, K.3
-
46
-
-
0030924992
-
Refinement of macromolecular structures by the maximum-likelihood method
-
Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53, 240-255.
-
(1997)
Acta Crystallogr
, vol.D53
, pp. 240-255
-
-
Murshudov, G.N.1
Vagin, A.A.2
Dodson, E.J.3
-
47
-
-
0001841380
-
On the rigid-body motion of molecules in crystals
-
Schomaker, V.; Trueblood, K. N. On the rigid-body motion of molecules in crystals. Acta Crystallogr. 1968, B24, 63-76.
-
(1968)
Acta Crystallogr
, vol.B24
, pp. 63-76
-
-
Schomaker, V.1
Trueblood, K.N.2
-
48
-
-
0025904209
-
Rigid protein motion as a model for crystallographic temperature factors
-
Kuriyan, J.; Weis, W. I. Rigid protein motion as a model for crystallographic temperature factors. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2773-2777.
-
(1991)
Proc. Natl. Acad. Sci. U.S.A
, vol.88
, pp. 2773-2777
-
-
Kuriyan, J.1
Weis, W.I.2
-
49
-
-
34548508518
-
Modelling rigid-body thermal motion in macromolecular crystal structure refinement
-
IUCr: London
-
Tickle, I. J.; Moss, D. S. Modelling rigid-body thermal motion in macromolecular crystal structure refinement. In IUCr99 Computing School; IUCr: London, 1999.
-
(1999)
IUCr99 Computing School
-
-
Tickle, I.J.1
Moss, D.S.2
-
51
-
-
0032562224
-
Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations
-
Rose, R. B.; Craik, C. S.; Stroud, R. M. Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations. Biochemistry 1998, 37, 2607-2621.
-
(1998)
Biochemistry
, vol.37
, pp. 2607-2621
-
-
Rose, R.B.1
Craik, C.S.2
Stroud, R.M.3
|